TransMedics Group’s (TMDX) Hold Rating Reaffirmed at Needham & Company LLC

TransMedics Group (NASDAQ:TMDX)‘s stock had its “hold” rating restated by analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports.

A number of other research analysts also recently issued reports on TMDX. Piper Sandler decreased their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Robert W. Baird lowered their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, Canaccord Genuity Group restated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $70.79 on Wednesday. The company has a fifty day moving average price of $68.43 and a 200 day moving average price of $89.16. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $177.37. The firm has a market cap of $2.38 billion, a PE ratio of 75.31 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Clear Creek Financial Management LLC acquired a new position in shares of TransMedics Group in the fourth quarter valued at approximately $352,000. Vaughan Nelson Investment Management L.P. boosted its stake in TransMedics Group by 9.9% in the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock valued at $22,547,000 after purchasing an additional 32,605 shares during the period. Baillie Gifford & Co. grew its holdings in TransMedics Group by 14.9% in the 4th quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock valued at $16,824,000 after buying an additional 34,947 shares in the last quarter. State of Michigan Retirement System bought a new position in TransMedics Group during the 4th quarter worth $6,734,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of TransMedics Group by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after buying an additional 6,634 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.